These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 17472544

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.
    Fenton C, Wellington K, Moen MD, Robinson DM.
    Drugs; 2007; 67(12):1749-65. PubMed ID: 17683173
    [Abstract] [Full Text] [Related]

  • 3. Drospirenone/ethinyl estradiol.
    Rapkin AJ, Sorger SN, Winer SA.
    Drugs Today (Barc); 2008 Feb; 44(2):133-45. PubMed ID: 18389090
    [Abstract] [Full Text] [Related]

  • 4. Oral contraceptives containing drospirenone for premenstrual syndrome.
    Lopez LM, Kaptein AA, Helmerhorst FM.
    Cochrane Database Syst Rev; 2012 Feb 15; (2):CD006586. PubMed ID: 22336820
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen.
    Parsey KS, Pong A.
    Contraception; 2000 Feb 15; 61(2):105-11. PubMed ID: 10802275
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A, De Leo V.
    Minerva Ginecol; 2007 Aug 15; 59(4):415-25. PubMed ID: 17923832
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of a new oral contraceptive containing drospirenone.
    Shulman LP.
    J Reprod Med; 2002 Nov 15; 47(11 Suppl):981-4. PubMed ID: 12497672
    [Abstract] [Full Text] [Related]

  • 13. Evolution of progestins. Focus on the novel progestin drospirenone.
    Thorneycroft IH.
    J Reprod Med; 2002 Nov 15; 47(11 Suppl):975-80. PubMed ID: 12497671
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. YAZ and the novel progestin drospirenone.
    Mishell DR.
    J Reprod Med; 2008 Sep 15; 53(9 Suppl):721-8. PubMed ID: 18980044
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder.
    Freeman EW, Kroll R, Rapkin A, Pearlstein T, Brown C, Parsey K, Zhang P, Patel H, Foegh M, PMS/PMDD Research Group.
    J Womens Health Gend Based Med; 2001 Sep 15; 10(6):561-9. PubMed ID: 11559453
    [Abstract] [Full Text] [Related]

  • 19. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.
    Oelkers WH.
    Climacteric; 2005 Oct 15; 8 Suppl 3():19-27. PubMed ID: 16203652
    [Abstract] [Full Text] [Related]

  • 20. Ethinyl estradiol/drospirenone (Yasmin): a newer oral contraceptive.
    Somma MA.
    Am Fam Physician; 2004 May 15; 69(10):2425-6. PubMed ID: 15168965
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.